Several retrospective studies suggested that the loss of CDX2 expression in colorectal cancers (CRCs) was associated with worse prognosis as well as several adverse prognostic variables, such as high histologic grade, BRAF mutations, and CpG island methylator phenotype positivity [16–18]. This evidence concerns the gene CDX2 and colorectal cancer.